
    
      OBJECTIVES:

        -  Assess the efficacy of the combination of cisplatin and etoposide after radical surgery
           in prolonging the relapse free and overall survival for stages I, II, and IIIA non-small
           cell lung cancer.

      OUTLINE: This a randomized study (treatment vs no treatment). Patients are stratified
      according to sex and to stage of disease (I vs II vs IIIA).

      Patient receives cisplatin and etoposide on days 1-3, every 28 days, for 3 cycles. Patient
      may receive radiation therapy after surgery at the discretion of the physician.

      PROJECTED ACCRUAL: Approximately 750 patients will be accrued over 3 years.
    
  